Molecular diagnostic firm Phoenix Diagnostics has gained Chinese regulatory approval for its liquid biopsy technique for breast cancer , the first of its kind to be cleared by the China Food and Drug Administration . The updated label cleared doctors to identify the mutation in blood samples when they are unable to access tissues for analysis. The company has developed a technique able to detect EGFR ##2 mutations in plasma cells by identifying circulating tumour cells through a non - invasive method .
Molecular diagnostic firm Phoenix Diagnostics has gained Chinese regulatory approval for its liquid biopsy technique for breast cancer , the first of its kind to be cleared by the China Food and Drug Administration . The company has developed a technique able to detect EGFR ##2 mutations in plasma cells by identifying circulating tumour cells through a non - invasive method .